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Abstract
Targeted sequencing of specific loci of the human genome is a promising approach for 
maximizing the efficiency of second-generation sequencing technologies for population-based 
studies of genetic variation. Here we describe microdroplet PCR, which performs 1.5 million 
separate amplifications in parallel, as an approach for enriching targeted sequences in the human 
genome. We initially designed primers to 435 exons of 47 genes that were selected for having a 
broad spectrum of sequence characteristics. Using this primer set we amplified the same six 
samples by both microdroplet and traditional singleplex PCR and sequenced the products using 
the Illumina GAII demonstrating that both methods generate similarly high quality data; 84% of 
the uniquely mapping reads fell within the targeted sequences, uniform coverage of ~90% of the 
targeted bases, greater than 99% accuracy in sequence variant calls, and high reproducibility 
between different samples (r2=0.9). We next scaled the microdroplet PCR to 3976 amplicons 
totaling 1.49 Mb of sequence, sequenced the resulting sample on both the Illumina GAII and 
Roche 454 platforms, and obtained data with equally high specificity and sensitivity quality. Our 
results demonstrate that microdroplet technology is well suited for processing DNA for massively 
parallel amplification of specific subsets of the human genome for targeted sequencing.
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Introduction
Technical advances in sequencing methods and instruments are rapidly transforming our 
ability to study both common and rare genetic variants in the human genome. Indeed, 
several human genomes have already been sequenced in their entirety1-4. However, for the 
time being, the cost for sequencing whole human genomes is prohibitive for addressing 
research questions in a large cohort of individuals. Three approaches are currently being 
utilized for enrichment of target sequences of interest. The first approach is traditional 
singleplex PCR which has been employed to examine in hundreds of samples large kilobase-
sized contiguous intervals5 or the exons of hundreds of genes6, 7. Although traditional PCR 
enriches target sequences with high specificity and sensitivity, it is difficult to scale the 
method to match the throughput of current sequencing instruments. The second approach is 
based on multiplex amplification of thousands of target sequences in a single tube by array 
synthesized padlock “molecular inversion” probes.8-10 Molecular inversion probes (MIP) 
allow for a highly efficient multiplex reaction due to the tethering of primer pairs by a DNA 
linker. However, published results show that while the captures are highly specific and 
represent upwards of 90% of the targets, there is greater than 100-fold range in coverage of 
the targeted sequences, and 34-42% of sequence capacity is consumed by either sequencing 
of primer sequences or the MIPs linker backbone9 (Supplemental Discussion). The third 
approach is based on hybridization with long oligonucleotides that are either matrix-bound 
or in solution to capture and pull-down the target sequences11-14. The hybridization-based 
methods have good capture rates, uniform coverage of target sequences, and good 
reproducibility. However, the methods are known to be biased to repetitive elements, which 
can result in a high proportion of non-uniquely mapping reads. Additionally, sequences that 
are highly homologous to other sequences in the genome cannot be individually targeted. 
We have developed an approach, involving microdroplet-based technology, which takes 
advantage of the high specificity and sensitivity of PCR and allows for massively parallel 
singleplex amplification of complex target sequences. The discrete encapsulation of 
microdroplet PCR reactions prevents possible primer pair interactions allowing for highly 
efficient simultaneous amplification of up to 4,000 targeted sequences and greatly reduces 
the amount of reagents required.
Results and Discussion
Microdroplet PCR Workflow
Microdroplet technology is particularly well suited for processing DNA for massively 
parallel amplification of sequencing targets by enabling the routine preparation of 1.5 
million separate PCR reactions from 20 microliters of template solution containing just 7.5 
micrograms of genomic-DNA. Microdroplet PCR is achieved through the following steps 
(Fig. 1): picoliter volume droplets of fragmented genomic DNA template are merged with 
pre-made primer pair droplets (Primer Library), pooled thermal cycling of the resulting PCR 
reactions (Droplet PCR), and destabilizing the droplets to release the PCR product (Break 
Emulsion) for purification and sequencing.
A key component of the microdroplet PCR process is the generation of a high quality primer 
library. The forward and reverse primers designed to amplify a targeted genomic interval are 
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combined at a concentration of 1.1 μM per primer (Fig. 1A), and reformatted as 8 picoliter-
volume primer pair droplets (encapsulation of the primer pairs in inert fluorinated carrier oil) 
by using a flow-focusing nozzle (Supplemental Fig. 1)15 to make a library element. Library 
elements are combined together such that each library element is represented by an equal 
number of droplets within the final primer library (Fig. 1A). The resulting primer library is 
mixed and quality tested for primer pair droplet size and uniformity, as well as library 
element representation (Supplemental Fig. 2).
The genomic DNA template mixture (Fig. 1) contains all of the components for PCR except 
for the primers and is prepared by fragmenting genomic DNA using DNase I to produce 2-4 
kb fragments (Fig. 1B) (Online Methods). On the microfluidic chip the template mixture is 
made into droplets and paired with primer pair droplets. The paired template and primer 
droplets enter the merge area on the microfluidic chip (Fig. 1C) at a rate of ~3000 droplets 
per second. As the primer pair droplets (8 pL) are smaller than the template droplets (14 pL) 
they move faster through the channels until they contact the preceding template droplet. 
Field induced coalescence of these droplet pairs16 results in the two droplets merging to 
produce a single PCR droplet which are collected and processed as an emulsion PCR 
reaction (Supplemental Fig. 3).
Validation phase - targeted sequences and DNA samples
To validate the microdroplet PCR approach we selected 47 genes distributed across the 
genome to determine the extent to which a set of PCR primer pairs could be chosen to 
simultaneous amplify numerous loci with a broad spectrum of sequence compositions using 
a single set of reaction conditions (Supplemental Table 1). Local DNA context, such as 
repetitive elements, GC content and sequence variants, can affect the ability of PCR primer 
pairs to work. One major drawback of PCR sample preparation is that allelic imbalanced 
amplification (greater efficiency of amplification for one of the alleles) due to variants in 
primer sites is sometimes observed17, 18. This type of PCR bias results in variant base 
calling errors, specifically heterozygous sites are called homozygous. Although the majority 
of SNPs shared among all populations have been discovered19 and are taken into account 
during primer design, population specific and rare variants are largely unknown. To check 
for biases in the ability of primers designed to the reference genome to amplify genomic 
DNA from individuals of different ethnicities, we included three HapMap samples of 
European and three of African descent. We also selected ~60% of the targeted sequences 
from three ENCODE20 intervals that were sequenced in five of the HapMap samples in our 
study as part of the HapMap Consortium21. This allowed us to compare the effect of allelic 
imbalanced amplification in intervals of the genome in which the majority of variation is 
known and can be accounted for during primer design versus intervals that are less well 
annotated for variation.
Of the 47 genes targeted in the validation phase, 29 are from ENCODE20 intervals, 8 are 
members of the Transient Receptor Potential ion (TRP) channel superfamily (included to 
test the ability to amplify and correctly align reads among family members with high 
nucleotide similarity), and the remaining 11 are candidates for deep venous thrombosis. Our 
primer design strategy (Online Methods) split the 435 exons of the 47 genes into 457 
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amplicons of varying sizes (119-956 bp) and GC content (24-78%) (Supplemental Tables 2 
& 3). The full amplicon sequences constituted 172.2 kb and the exonic sequences comprised 
75.9 kb (44%). It is important to note that the primer selection process did not attempt to 
minimize off-exon sequence, and thus if desired the ratio of exon:off-exon sequences in the 
amplicons could be increased. The primer pairs were designed and put into production in a 
single pass; there was no redesign of failed primer pairs.
Specificity of amplification
Using the validation phase 457 PCR primer set we amplified the six DNA samples using 
both traditional singleplex and microdroplet PCR. After the PCR amplification step all 
samples from the two methods were processed simultaneously through library creation and 
sequencing to ensure that any differences in the data were due to the amplification methods. 
Samples were labeled with a DNA barcode during the library preparation step and for each 
PCR method all six bar-coded samples were run on a single lane (Online Methods). The two 
lanes generated equivalent amounts of sequence data with each sample having an average of 
1.27 million reads passing quality filters (Table 1).
To determine how well the 457 primer pairs specifically amplified the targeted sequences 
we calculated the percentage of filtered reads that mapped to a targeted amplicon. 
Considering all six samples 82% and 73% of filtered reads successfully mapped to the full 
amplicon sequences for the traditional and microdroplet reactions, respectively (Table 1). 
Considering only uniquely mapping reads 96% (231.69 Mb) of the traditional and 84% 
(202.15 Mb) of the microdroplet reads map back to the amplicons. After trimming primer 
sequences from the amplicons, which account for 12% of the total sequence, of the uniquely 
mapping reads 91% of the traditional and 80% of the microdroplet reads mapped to targeted 
sequences. Of the reads mapping to the amplicons, 55.6% and 51.1% map to the exons for 
the traditional and microdroplet PCR, respectively. In the microdroplet PCR reaction the 
ratio of input genomic DNA to amount of final PCR product is considerably greater than it 
is for traditional PCR (Online Methods), which may explain the ~15% difference between 
the two methods in reads that map off target. Overall, these data demonstrate that the 
microdroplet PCR enrichment method generates a high proportion of target sequence to 
background sequences.
Coverage uniformity and reproducibility
Uniformity of sequence coverage across targeted sequences is important because it 
determines the average depth to which samples have to be sequenced to have optimal 
sensitivity for variant calling. If the coverage differs greatly across targeted bases then one 
has to sequence deeply to adequately cover underrepresented bases. We initially examined 
how the base by base sequence coverage differs within individual amplicons. Visual 
inspection of coverage plots of individual targeted sequences (Fig. 2A) showed that there is 
typically a two to three-fold variation in the per-base sequence coverage depth across the 
amplicon. Interestingly, a noticeable dip in sequence coverage occurs at the transition from 
the 36th to 37th base pair in the amplicon, which is likely due to more reads (36 bp in length) 
starting at base one compared to bases 2 to 5. We next compared the coverage uniformity 
across all targeted bases for the six samples and the two PCR methods. The six samples had 
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slightly different sequence yields in the traditional and microdroplet PCR methods (Table 1) 
and therefore we normalized the coverage (divided the coverage of each base by the mean 
coverage of all targeted bases) so we could directly compare their coverage distribution plots 
(Fig. 3A, 3B). We first determined the percentage of targeted bases with sequence coverage 
between 1/5 to 5 times the mean. For traditional PCR, 92.8% of all bases fell within this 
range with 99.6% of the bases covered by at least one read (Fig. 3A, Supplemental Table 4). 
The microdroplet PCR showed similar results with 90.2% of all bases falling within 1/5 and 
5 times the mean with 99.8% of all targeted bases covered by at least one read (Fig. 3B). 
These results indicate that for studies using microdroplet PCR amplified DNA and Illumina 
GA sequencing to an average depth of 25X that ~ 90% of the bases will be covered with 5 or 
more reads and with ~98% of all bases covered by at least a single read.
The consistency and reproducibility of coverage across targeted bases from sample to 
sample is of high importance for population studies. This is due to the fact that coverage is 
directly correlated with accuracy in base calling and to perform sequence-based association 
studies the same bases need to be analyzed across numerous samples. We compared the 
mean coverage of each amplicon between samples showing that reproducibility was 
excellent between samples with high correlations of amplicon coverage within a PCR 
method (average Lin's concordance: r2 = 0.88 traditional PCR, r2 = 0.91 microdroplet PCR) 
(Fig. 4A, B). On the other hand, coverage depth of specific amplicons between the two PCR 
methods varied (Fig. 4C, D), most likely due to differences in PCR chemistry and cycling 
conditions. Interestingly, of the 457 amplicons there was only one that failed completely (no 
reads) in four samples with the traditional PCR and a different amplicon that failed 
completely in three individuals with the microdroplet PCR. In both PCR methods >99.6% of 
the amplicons were successful, defined as a mean coverage greater than 5. Coverage was 
similar for the European and African ancestry samples and for the targeted sequences in 
ENCODE and non-ENCODE intervals. These data demonstrate that microdroplet PCR 
results in consistent and reproducible coverage of targeted sequences.
Accuracy of sequence variant calls
We evaluated the accuracy of variant bases called in the PCR amplified sequences for the 
six samples by comparison to HapMap genotypes for ~450 SNPs (Table 2a). There were a 
total of 2424 comparisons for the tradition PCR across the six samples with 22 of the 
comparisons being discordant for a consensus rate of 99.1% (Table 2a). The microdroplet 
PCR had the same consensus rate with 22 discordances out of 2390 comparisons. In both 
PCR methods ~ 2.5% of the HapMap variant sites were uncalled primarily due to low 
coverage, poor mapping quality, or the presence of neighboring variants. There was no 
observed difference in call rate or concordance between either the ENCODE and non-
ENCODE intervals or between samples in the two ethnicity groups. Importantly, the two 
PCR methods were concordant with each other at all positions discordant with the HapMap. 
Of the 22 loci discordant with HapMap the errors fell into three classes: 1. nine are 
homozygous reference genotypes with HapMap homozygous alternate; 2. five are 
heterozygous genotypes with HapMap homozygous reference; and 3. eight are homozygous 
genotypes with HapMap heterozygous (Supplemental Table 5). Further examination of the 
discordant bases revealed most of those in class 1 are present in a single targeted sequence 
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with a highly similar homolog in the genome. Our sequencing reports the reference alleles 
for the target while HapMap calls the alternate alleles, which correspond to the fixed bases 
at those positions in the homolog. Inspection of the ENCODE traces revealed that the 
amplicons appeared to be amplifying both homologs as supported by all individuals being 
heterozygous at the differing positions (Supplemental Fig. 4). Class 2 and 3 errors most 
likely represent missed heterozygous calls in the HapMap and sequence data, respectively. 
Because allelic imbalanced amplification is a concern when performing PCR enrichment we 
focused on the eight Class 3 errors. Manual inspections of ENCODE sequence traces for 
five of these variants revealed that 4 are homozygous calls consistent with our sequence 
data. To determine if allelic bias during the PCR reaction was common among concordant 
variant calls we calculated the number of reference and alternate allele observations at 
heterozygote sites in the six samples. No skew was observed with 51.6% (CV 12%) and 
51.1% (CV 13%) of the reads reporting the reference allele in traditional and microdroplet, 
respectively with no difference between ENCODE and non-ENCODE sites. Our analysis 
indicates that allele biased amplification results in only ~0.1% of the variants to be called 
incorrectly (≤ 5 out of 2390) and that >50% of the discrepancies between HapMap 
genotypes and variant calls in our sequence data are due to errors in the HapMap data.
To estimate the false positive rate we analyzed the variants identified in the targeted genes in 
the ENCODE intervals sequenced in five of the samples as part of the HapMap project. A 
total of 1122 variants at 442 positions were identified in these genes, of which 62 positions 
were not listed as variants in the HapMap data (Supplemental Table 6). Thirty-five of these 
positions are listed as variant in dbSNP suggesting that they are not false positives. Of the 27 
positions not listed in dbSNP, 12 have concordant calls between the traditional and 
microdroplet PCR for at least one sample suggesting they may be true novel variants. The 
remaining 15 sites were either discrepant in the traditional but not in the microdroplet PCR 
(1 position, 3 variant calls) or discrepant by one method and the position did not pass quality 
filters in the second method (14 positions, 15 variant calls). These analyses suggest that the 
false positive rate of the sequence data is < 1.6% (≤18 of 1122 variant calls).
Scale up phase – selection of target sequences
To efficiently perform population-based sequencing studies using next generation 
sequencing platforms it is important to be able to simultaneously examine large numbers of 
targeted sequences. In this next phase we tested the ability of the microdroplet PCR to scale-
up to 3976 primer pairs, which in total amplify 1.49 Mb of sequence, of which 645 kb (43%) 
consists of exonic sequence. We also tested the compatibility of this enrichment process 
with other next generation technologies (Online Methods). To further test the robustness of 
the microdroplet PCR process we choose primer pairs with widely varying characteristics, 
including primer lengths (17 bases - 30 bases), primer Tm (55.4°C - 61.2°C), amplicon 
length (299 bp - 659 bp) and amplicon GC content (25.1% - 81.5%), to determine how this 
affected the outcome of targeted sequence amplification.
Specificity of amplification
A single HapMap sample, NA18858, was amplified using the scale-up phase 3976 
amplicons by microdroplet PCR (Online Methods). The resulting amplified material was 
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then divided into two aliquots and sequenced by both the Illumina GA II (short-read 
platform) and Roche 454 FLX (long read platform). The Illumina run generated >10 million 
quality single-end reads with similar fractions, as those observed in the validation phase, of 
both total reads (76%) and uniquely mapped reads (79%) successfully mapped to the 
trimmed amplicon sequences (Table 1). The Roche 454 run generated ~350,000 quality 
reads with ~94% of these mapping to the full amplicons. The larger fraction of Roche reads 
mapping to targets is likely due to the fact that the microfluidic PCR amplified DNA is not 
fragmented in the Roche 454 library preparation protocol and therefore the non-specific 
genomic DNA carryover from the amplification step (~2 to 4 kb in length) is too long to be 
efficiently used in library generation. These results indicate that even when simultaneously 
amplifying 3976 targeted sequences microfluidic PCR generates a high ratio of target 
sequence to background sequence.
Coverage uniformity and accuracy of variant calls
We evaluated the ability to uniformly capture the intended target across all 3976 amplicons. 
Only one amplicon failed completely resulting in zero mapping reads for both the Illumina 
and Roche 454 platforms. After trimming primer sequences we enriched for a total of 1.35 
Mb of sequence, on the Illumina platform 99.8% of the bases were covered by 1 or more 
reads, of which 96.6% fell within 1/5 and 5 times the mean coverage (Fig. 3C). Furthermore, 
90% of all amplicons had coverage at 1/5 the mean or greater for at least 95% of the basis, 
for 5X coverage this increased to 98% of the amplicons. Coverage was lower for amplicons 
greater than 70% GC content but was unaffected by amplicon length (Supplemental Fig. 5). 
The proportion of reads mapping to exons is closely proportional to the fraction of exonic 
sequences in the amplicons. The uniformity of coverage was slightly decreased when 
sequenced on the Roche 454 platform, with 93.7% of the bases covered by at least 1 read 
and 88.4% falling within 1/5 and 5 times the mean (Fig. 3C). The lower coverage uniformity 
observed in the Roche 454 sequence results from sequencing the amplicon ends without 
shearing the input DNA in the library preparation, and therefore the middle bases of short 
amplicons have high coverage and the middle bases of longer amplicons receive little or no 
coverage (Fig. 2B).
To examine accuracy, variant bases called in the Illumina and Roche 454 sequences were 
compared to 2226 HapMap genotypes. The Illumina sequence had a call rate of 99.3% with 
26 discordant SNPs, while the Roche 454 sequence had a call rate of 92.3% with 31 
discordant SNPs. The discrepant variants overlapped at 21 sites between the two sequence 
platforms and largely fell into the same error classes observed in the validation phase, with 
the exception that several discrepant Roche 454 SNPs were present in homopolymer 
sequences (Supplemental Table 7) consistent with previous observations.18 The Roche 454 
lower call rate is related to the low coverage bases in the middle of longer amplicons (Fig. 
2B). Overall this data shows that increasing the number of amplicons in the microdroplet 
PCR reaction almost an order of magnitude does not affect the resulting data quality.
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Discussion
Important parameters to consider when choosing an enrichment method for targeted 
sequencing include: uniformity of coverage of targeted sequences; the detection rate and 
calling accuracy of sequence variants; the efficiency of the enrichment over background 
sequences; universality of the capture method (fraction of genome that can be uniquely 
captured); and the multiplicity of the reaction (amount of sequence that can be targeted). 
Compared with other enrichment methods microdroplet PCR generates substantially greater 
uniform coverage of targeted sequences (Supplemental Discussion and Supplemental Table 
8). Importantly the high uniformity of coverage results in a higher variant detection rate: 
microdroplet PCR (94.5%), solution-based hybridization (64%-89%)14, Molecular 
Inversion Probe (75%)9. The accuracy of called variant bases is currently high across all 
enrichment strategies. Likewise the proportion of reads mapping to targeted sequences is 
similar (~65%) across the different enrichment methods9, 14. Microdroplet PCR is a 
universal method allowing for the unique capture of most sequences, even those highly 
similar to other sequences in the genome; by anchoring a primer in the divergent portion of a 
homologous sequence or in an adjacent unique region, almost any interval can be 
specifically targeted. For hybridization-based methods, repetitive elements or homologous 
exons cannot be individually captured. For many population studies it will be desirable to 
simultaneously examine large numbers of targeted sequences. We have demonstrated the 
ability of microdroplet PCR to enrich for 4,000 targeted sequences in a single tube per 
sample, and are working towards scaling this to 20,000 targets (~7.5 Mb, ~1/10th the exome) 
using an expanded content format with 5 sets of primers in each droplet (Online Methods) 
and no other changes to the workflow. The Molecular Inversion Probes method has been 
used to enrich for 13,000 targeted sequences with high performance9 and the solution-based 
hybridization approach has shown the ability to target 22,000 sequences simultaneously14. 
Therefore the multiplicity of the targets and the scalability of these methods enable large 
number of samples to be examined in population studies. Recently an array-based capture 
has been employed to target 26.6 Mb of coding exons of 12 individuals with similar 
mapping efficiency as that of solution based hybridization22. While the approach has 
excellent concordance and uniformity, array-based capture is difficult to scale for population 
studies in individual laboratories.
The microdroplet PCR process proved to be extremely efficient with greater than 99.6% of 
all amplicons being successful (mean coverage greater than 5) and with highly reproducible 
amplification of targeted sequences between samples. Allelic amplification bias resulted in 
surprisingly few known variants to be incorrectly called, further attesting to the robustness 
of the process. An improved ability to remove non-specific genomic DNA carryover (Online 
Methods) would increase the enrichment observed on short-read sequence platforms by 
~15% to that observed on the Roche 454. The requirement for 7.5 micrograms of starting 
DNA used in this study limits the applicability of microdroplet PCR for samples with 
limited quantities. While optimization has reduced the current requirement to 2 micrograms 
we are working on further improvements to reduce the amount of required starting material 
to nano-gram quantities of DNA (Supplemental Discussion).
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Overall, our study shows that the data generated using microdroplet PCR as an enrichment 
method is well suited for performing sequence-based association studies.
Online Methods
A. Microdroplet Based PCR Workflow
Primer Library Generation—Preparation of a high quality primer library is achieved 
through several steps. Primer pairs are designed and synthesized to amplify the targeted 
genomic regions. The forward and reverse primers for each amplicon are combined at a 
concentration of 1.1 μM per primer (Fig. 1A) and reformatted as 8 picoliter primer pair 
droplets by using a flow-focusing nozzle (Supplemental Fig. 1) in a microfluidic chip15. 
Library elements are tested for droplet size and uniformity (Supplemental Fig. 2) and mixed 
together such that each library element is represented by an equal number of droplets within 
the primer library (Fig. 1A).
Primer Library Quality Control—As shown in Supplemental Figure 2 the method for 
determining library element representation consists of 1) measuring the total volume of 
primer solution that is made into droplets from each library element and 2) measuring the 
distribution of droplet sizes present in each library element. These two measurements are 
made by using a flow sensor and a stroboscopic imaging system. The time integral of the 
measured infusion rate on the flow sensor provides a measure of the total volume of primer 
solution made into droplets for each library element. The stroboscopic imaging system 
collects images at a rate of 10 per second and each image contains roughly 20 droplets. This 
sampling of roughly 200 droplets per second of the 8000 per second generated is used to 
measure a representative distribution of the droplet volumes for each library element. The 
pass criteria consist of all library elements being represented with greater than 90% of the 
droplets within a window between 7.0 and 9.0 pico-liters. A bar graph of the total count of 
droplets for each library element from the stroboscopic imaging system provides a snapshot 
of the uniformity achieved.
The primer library for the 3976 amplicon library was made from 11 separate 384-well plates 
in a process whereby an equal number of droplets were made from each well on a given 
plate and stored in a collection vial for that plate. The 11 collection vials were then mixed 
and an equal volume of emulsion was transferred from each collection vial into a pooling 
vial; with the exception of the last vial which had a proportionally smaller volume 
transferred as it contained fewer library elements. Hence, the appropriate QC metric is the 
droplet count for each library element that went into a given collection vial and 11 separate 
droplet count graphs were generated; Fig. S2d being representative. In the case of the 457 
library, all library elements were collected directly into the final pooling vial and the QC on 
the number of droplets was appropriately conducted on all 457 library elements as shown in 
S2b. The histograms of droplet size distribution shown in Fig. S2c is for the pooled library 
containing all library elements.
Genomic DNA Fragmentation and Nick Translation—Genomic DNA is fragmented 
using DNase I to produce 2-4 kb fragments and nick translated to incorporate biotinylated 
nucleotides into the genomic DNA fragments. Fragmentation of the genomic DNA to 2 – 4 
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kb allows for optimal template size for performing PCR in droplets. Incorporation of 
biotinylated nucleotides during the nick translation step allows the genomic DNA to be 
removed during the Genomic DNA Removal step to reduce the amount of genomic DNA 
fragments entering into the construction of the Illumina GA II and Roche 454 sequencing 
libraries.
The genomic DNA samples are processed on ice: 7.8 μg of genomic DNA in 25 μL nuclease 
free water (Fisher, 50843418), 37.5 μL of NEBuffer 2 (NEB, B7002S), 37.5 μL of a mixture 
of 1 mM each dCTP, dGTP, dTTP (NEB, N0446S), 18.75 μL of 0.4 mM Biotin-14 dATP 
(Invitrogen, 19524-016), 211.25 μL nuclease free water (Fisher, 50843418), 7.5 μL DNA 
polymerase I (10 units/μL) (NEB, M0209S), 37.5 μL of DNase I (NEB, M0303S) at a 
concentration determined by titration to achieve a 2-4 kb size distribution. The Genomic 
DNA fragmentation reaction mix is incubated at 15°C for 90 minutes and the reaction 
stopped by adding 37.5 μL of 0.5 M EDTA, pH 8.0 (Ambion, AM9260G). The DNA is 
purified over a Qiagen MinElute PCR purification column (Qiagen, 28004 (28006)) using 
the manufacturer's recommended conditions except for eluting with 13 μL of 10 mM Tris-
Cl, pH 8.5.
Genomic DNA Template Mix—9.3 μL of the purified Genomic DNA Fragmentation 
reaction was added to 2.5 μL 10x High-Fidelity Buffer (Invitrogen, 11304-029), 1.6 μL of 
MgSO4 (Invitrogen, 11304-029), 0.8 μL 10 mM dNTP (New England Biolabs, NO447S/L), 
4.0 μL Betaine (Sigma, B2629-50G), 4.0 μL of RDT Droplet Stabilizer (RainDance 
Technologies, 30-00826), 2.0 μL dimethyl sulfoxide (Sigma, D8418-50ml) and 0.8 μL 5 
units/μL of Platinum High-Fidelity Taq for a final volume of 25 μL.
RDT 1000: Merge—PCR droplets are produced by combining a single droplet from the 
primer library with a single genomic DNA template droplet (Supplemental Fig. 3). To 
achieve this, 20-uL of the Genomic DNA Template Mix is delivered to a microfluidic chip 
where it generates 14 pL template droplets at a rate of 3000 droplets per second 
(Supplemental Fig. 3b). In a separate channel primer library droplets are delivered onto the 
same chip (Supplemental Fig. 3a) and spaced to enter the channel carrying the genomic 
DNA template droplets at a one-to-one ratio (Supplemental Fig. 3c). As the primer library 
droplets are smaller than the template droplets, they move faster and catch up to the genomic 
DNA template droplets so that they enter the merge area on the chip (Supplemental Fig. 3d) 
as droplet pairs. In the merge area, the two droplets (template and primer pair droplets) 
coalesce in the presence of an external electric field16 to produce a single PCR droplet. The 
fidelity of the microfluidic flow enables one to set-up individual PCR reactions at a rate of 
3000 per second. Over the period of roughly 10 minutes the 20-uL Genomic DNA Template 
Mix is processed into greater than 1.5 million PCR droplets (Supplemental Fig. 3e). The 
collection of PCR droplets represents essentially equal numbers of individual reactions from 
each of library elements. The PCR droplets are collected in a single standard PCR tube 
(Axygen, VWR, 22234-054) for thermal cycling and further processing (Supplemental Fig. 
3f). The whole process can be viewed in the attached movie (Supplemental Movie 1) 
depicting the delivery of the primer pair droplets and the formation of the genomic DNA 
template droplets that pair together in a 1:1 ratio and merge into PCR droplets which are 
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collected for downstream highly parallel amplification of over a million single-plex PCR 
reactions.
PCR Amplification—Samples are cycled in a Bio-Rad PTC-225 thermocycler as follows: 
initial denaturation at 94°C for 2 minutes; 55 cycles at 94°C for 15 seconds, 58°C for 15 
seconds, and 68°C for 30 seconds; a final extension at 68°C for 10 minutes and then hold at 
4°C.
Breaking Emulsion—After amplification the PCR droplets are broken to release the PCR 
products from each individual emulsion reaction droplet. An equal volume of RDT 1000 
Droplet Destabilizer (RainDance Technologies, 40-00830) is added to the collected PCR 
emulsion, the tube is vortexed for 15 seconds and then spun in a microcentrifuge for 10 
minutes. A Gel-Loading Aerosol-Barrier Tip (Fisher Scientific, 02-707-172) is used to 
remove the oil from below the aqueous phase.
Genomic DNA Removal—110 μL of streptavidin beads (NEB, S1420S) in a 1.5 mL 
microcentrifuge tube are spun briefly in a microcentrifuge and placed on a magnetic 
separation rack (NEB, S1506S) for 30 seconds, the supernatant is removed and discarded. 
The beads are resuspended in 110 μL of binding buffer (0.5 M NaCl, 20 mM Tris-HCl (pH 
7.5), 1 mM EDTA) by vortexing, briefly spun in a microcentrifuge and placed on a magnetic 
separation rack for 30 seconds, the supernatant is removed and discarded. The washed beads 
are resuspended in 110 μL of binding buffer and 50 μL of the beads are added to the broken 
amplicon emulsion. The beads are vortexed and then incubated for 10 minutes rotating on a 
Barnstead Labquake Tube Rocker. The beads are placed in a magnetic separation rack for 30 
seconds and the supernatant transferred to a new 1.5 mL microcentrifuge tube. 50 μL more 
of the beads are added to the supernatant followed by vortexing and placement on the 
magnetic separator rack for 30 seconds. The supernatant was removed to a new 1.5 mL 
microcentrifuge tube. The DNA is then purified over a Qiagen MinElute PCR purification 
column (Qiagen, 28004) using the manufacturer's recommended conditions and eluted using 
11 μL of Elution Buffer (10 mM Tris-Cl, pH 8.5). 1 μL of the eluant is run on an Agilent 
Bionanalyzer using the DNA 1000 Kit (Agilent, 5067-1504) to determine the yield for the 
amplicons. Typical yields originally were 100 – 300 ng. With improved conditions the 
typical yields are currently 200 – 600 ng.
B. Validation Phase
Genomic DNA samples—Six HapMap-DNA samples23 from unrelated individuals of 
different ethnic backgrounds were obtained from the Coriell Institute for Medical Research 
(www.coriell.org). Three were Caucasian descent (CEPH; NA11832, NA11992, and 
NA12006) and three were African descent (YRI; NA18489, NA18505, and NA18517). Five 
of these samples are part of the extended HapMap panel genotyped on the Affymetrix 6.0 
and Illumina 1M arrays.
Target exons—In total, 435 exons from 47 genes (Supplemental Table 1) were targeted, 
of which 197 exons from 28 genes are in the ENCODE intervals sequenced in our study 
samples as part of the HapMap project and were selected to serve as reference standards. 
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The remaining 19 genes (238 exons) included 8 members of the TRP channel superfamily 
(147 exons) to test for the ability to amplify and correctly align reads among gene family 
members with high nucleotide similarity.
Primer Design and Synthesis—The sequences for the 435 exons were masked for both 
repetitive elements (RepeatMask, UCSC Genome Browser) and known SNPs (dbSNP128). 
Exons larger than 600 bp were split into smaller elements to yield 457 targets for primer 
design. A five stage approach utilizing Primer3 (http://primer3.sourceforge.net/) for design 
was employed with stage one using the most stringent design parameters and the relaxing of 
these parameters at each subsequent stage (Supplemental Table 2). At the different stages 
the parameters altered include the amount of flanking sequence around the targeted region 
that Primer3 was allowed to use for design (200 & 300 bp), Tm (59.5-60.5 & 57.5-62.5), 
and removal of repeat masking of either the 5′ or 3′ flanking sequences. Primer length 
(18-27 nucleotides) was kept constant at all five stages. The majority (424) of the amplicons 
designed in the first stage (200 bp flanking sequence, Tm = 59.5-60.5, repeat masking of 
both 5′ and 3′ flanking sequence). The remaining 33 amplicons were designed within the 
next 4 stages. The 457 amplicons had a mean size of 400 bp ranging from 120 to 957 bp 
(Supplemental Table 3). The primer sets were obtained from Integrated DNA Technologies, 
Inc. with 5′-blocked end modification (Amino Modifier C6) as described.24 The 5′ blocked 
PCR primers were used to prevent their ligation to linkers in the library creation stage and 
thus over-representation in sequence coverage of the amplicon ends.
Traditional PCR amplification—We performed traditional PCR amplification of the 457 
amplicons in individual reactions as follows: 5 ng of genomic DNA was amplified using 
1.25 uM of each primer, 0.5 ul Titanium Taq DNA Polymerase (Clontech), 0.5 mM dNTPs, 
32 mM Tricine, 4% DMSO, 60 mM Trizma, 3.2 mM MgCl2, 17 mM (NH4)2SO4 and 0.6X 
MasterAmp PCR Enhancer (EPICENTRE Technologies) per reaction, in a volume of 12 ul. 
The reactions were performed using a GeneAmp PCR System 9700 thermocycler (Applied 
Biosystems): initial denaturation at 96°C for 5 min; 55 cycles at 96°C for 2 sec and 60°C for 
2 min; and a final extension at 50°C for 15 min. Following traditional PCR, the 457 
amplicons generated from each genomic DNA sample were pooled in equal volume 
amounts. The 55 cycles of PCR were to exhaust the primers in each reaction in order to 
generate a uniform amount of each amplicon regardless of the efficiency of the PCR 
primers.
Library preparation for Illumina GA—The Illumina GA libraries for both the 
microdroplet and traditional PCR samples were made in parallel according to the 
manufacturer's instructions except for the following modifications. The fragmentation step 
was performed by shearing ~130-300 ng of the pooled PCR amplicons using Adaptive 
Focused Acoustics (Covaris S1, Covaris, Inc.) with the following conditions: Duty cycle, 
20%; Intensity, 8; Cycles per burst, 200; Time, 6 minutes. This resulted in fragmented 
amplicons an average size of ~100 bp ranging from 50 to 175 bp. Paired-end adaptors used 
in ligation contained a different 4-bp barcode for each HapMap sample (NA11832-CAGT, 
NA11992-CTCT, NA12006-CCCT, NA18489-CACT , NA18505-CTGT, NA18515-CCGT) 
allow multiplexing of all six samples into a single lane24. The barcodes were sequenced as 
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bases 1-4 of the sequencing chemistry, reads were binned by barcode and trimmed to start at 
base 5 for downstream analysis. Because we have observed slight biases in sequencing 
efficiency between barcodes the same barcode for each sample was used for both 
microdroplet and traditional PCR. Following size selection, libraries were enriched by 12 
(NA18517 for both microdroplet and traditional methods) or 15 (all other samples) cycles of 
PCR amplification using 10 ul of ligated product per library. Post enrichment the samples 
were quantified by Picogreen in quadruplicate and normalized to a 10 nM concentration. 
The six indexed libraries generated from the microdroplet PCR were combined together into 
one pool and the six libraries generated by traditional PCR were combined together into a 
second pool. 2.3 pM of each pool was then loaded into two separate lanes of the flow cell 
and sequenced using Illumina paired end cluster generation kit v1 and SBS kit v.2 for 40 
cycles on each of the two reads.
C. Scale-up Phase
Genomic DNA Sample—A single HapMap-DNA sample23 of Yoruban descent 
(NA18858) was obtained from the Coriell Institute for Medical Research (www.coriell.org).
Target Exons, Primer Design and Synthesis—3976 PCR primer pairs were selected 
from a published set designed to amplify the coding regions of 13,062 genes25. The PCR 
primers were a subset of those published chosen to investigate how varying primer lengths 
(17 bases - 30 bases), primer Tm (55.4°C - 61.2°C), amplicon length (299 bp - 659 bp) and 
amplicon GC content (25.1% - 81.5%) affected the outcome of the targeted sequence 
enrichment and sequencing process. As described25 primer pairs were designed using 
Primer3 (http://primer3.sourceforge.net/), were required to be at least 50 bp outside the exon 
boundary, and avoided the presence of known SNPs in the five most 3′ bases. Primers were 
synthesized at Integrated DNA Technologies, Inc.
Library Preparation for Illumina GA and Roche 454—In the scale-up phase a single 
HapMap sample, NA18858, was amplified using 3976 amplicons by the microdroplet-based 
PCR workflow. The resulting amplified material was then divided into two aliquots and 
sequenced by both the Illumina GAII and Roche 454 platforms.
Illumina GA Library Preparation—Prior to the standard protocol for library generation 
on the Illumina GAII, the following steps were performed with the amplicons obtained from 
the sequence enrichment procedure. The amplicons were chloroform extracted and ethanol 
precipitated. Using the New England BioLabs Quick Blunting kit (E1201L) the fragments 
were blunt ended and phosphorylated. The fragments were then concatenated by ligation 
overnight at 25°C using the New England BioLabs Quick Ligation kit (M2200L). The 
concatenated amplicons were fragmented to 400 bp by Adaptive Focused Acoustics 
(Covaris S1, Covaris, Inc.) using the following settings: Mode, Frequency sweeping; 
Number of cycles, 1; Bath temperature limit, 20 degrees Celsius; Total process time, 3 
minutes; Number of treatment, 4; Total time per treatment, 45 seconds; Duty cycle, 10%; 
Intensity, 5; Cycles per burst, 200. The sheared DNA was purified using a Qiagen QIAquick 
PCR purification column (28106) at which point the sample entered the standard Illumina 
GA library preparation protocol at the blunt ending and phosphorylation step, which follows 
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genomic DNA fragmentation. All subsequent steps were according to the standard library 
preparation protocol for sequencing on the Illumina GAII. Following library preparation the 
sample was sequenced on an Illumina GAII using two lanes of a flow cell.
Roche 454 FLX Library Preparation—Library generation for 454 FLX sequencing was 
carried out using the manufacturer's standard protocol. The ends of the PCR amplicons 
generated in the sequence enrichment procedure were made blunt and phosphorylated using 
the standard 454 protocols. The 454 sequencing adaptors were directly ligated onto the ends 
of the amplicons. The amplicons with the ligated 454 adaptors were then processed through 
the remainder of the library preparation protocol according to 454 FLX standard procedures 
for Low Molecular Weight DNA samples. The sample was sequenced using one half of a 
PicoTiterPlate on the Roche 454 FLX instrument.
D. Ratio of input genomic DNA to amount of final PCR product
In the microdroplet PCR reaction the ratio of input genomic DNA to amount of final PCR 
product is considerably greater than it is for traditional PCR, which may explain the ~15% 
difference between the two methods in reads that map off target. It is likely that a greater 
amount of genomic DNA enters into the Illumina GA libraries for the microdroplet PCR 
versus the traditional PCR method.
In the microdroplet PCR method 7.8 ug of DNA is input into the nick translation reaction. 
After nick translation and purification ~4.5 ug of DNA is input into the template buffer for 
droplet generation and merging with the library droplets. The amplicon yield for the 
validation phase library with 457 primers ranged from 128 ng to 300 ng.per sample for all 
amplicons combined. The amplicon yield for the scale up phase library with 3976 primers 
was 200 ng for all amplicons combined.
In the traditional PCR, 5 ng of DNA is input into each of the 457 reaction mixtures (2.3 ug 
total). The yield ranged from 271ug to 413 ug per sample for all amplicons combined.
E. Data Analysis
Illumina GAII - Mapping, Amplicon Efficiency and Coverage Uniformity—All 
samples sequenced on the Illumina GAII were processed through the Illumina pipeline v1.3 
using default parameters. High quality filtered reads were mapped to the entire human 
genome (hg18) reference sequence (NCBI Build 36.1), using Maq v0.7126 default 
parameters except for insert size (-a 150) and mismatches (-n 3). Uniquely mapping reads 
were considered reads with a mapping quality score of 20 or greater corresponding to a 1% 
chance of being incorrectly mapped. The coverage uniformity analysis calculated coverage 
at the predicted amplicons after trimming primer sequences. Mean amplicon coverage and 
total coverage plots were produced using custom scripts and the statistics package R. None 
of the 457 amplicons in the validation phase failed (mean coverage less than 1) across all six 
samples. For traditional PCR there were 4 failures of a single amplicon across the 6 samples, 
this amplicon performed well for microdroplet-based PCR. Likewise a different amplicon 
failed for 3 of the 6 microdroplet-based amplified samples but performed well in the 
traditional PCR.
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Illumina GAII - Variant Detection and Quality Assessment—Mapped reads from 
the coverage analysis were used for variant detection using default parameters of the Maq 
SNP calling algorithm except for the following parameters (-w 10, -N 2, -W 2). Variants 
were additionally filtered using the MAQ variant consensus score. This value was 
empirically derived for the validation and scale-up phases by plotting the variant call rate 
against the consensus score and selecting the highest score just prior to a drop in call rate. 
The cutoff for the validation phase (paired end reads) was set at 30 while the scale up phase 
(single end reads) was filtered at a score of 50. The need to use a higher Maq quality cutoff 
for single versus paired end reads is well characterized 6.
A combined set of both HapMap Phase II and III genotypes were used for comparisons, the 
forward strand calls were downloaded from the HapMap website (http://www.hapmap.org). 
Concordance was calculated by the number of single nucleotide variants called the same 
between the HapMap and sequence data divided by the number of single nucleotide variants 
in the HapMap data for which the sequences data had a MAQ variant consensus greater than 
the derived threshold as well as coverage of 5 reads or more at the base. Bases with a 
consensus score less than the threshold or fewer than 5 reads covering the site were masked 
as no calls and are counted against the variant detection rate score but not the concordance 
rate. Calls were considered discordant regardless of the type of discordance, for example, an 
AB to AA error affected the concordance score the same as an AA to BB error.
Roche 454 – Mapping and Variant Detection and Quality Assessment—Data 
from the sequencing run on the 454 FLX was processed using 454′s standard data analysis 
software. For the amplicon amplification efficiency and coverage uniformity analyses high 
quality filtered reads were mapped to the predicted amplicon sequences, which were 
extracted from the hg18 reference sequence (NCBI Build 36.1), using the default parameters 
of the command line version of the Newbler module GS Mapper (version 2.0.00.20-64).
Prior to performing variant detection analysis the high quality filtered reads were mapped to 
the entire human genome reference sequence (hg18). Reads that aligned to one of the 
predicted amplicon sequences in the coverage analysis but matched to a homologous region 
when mapped to the entire human genome were removed prior to variant detection. Variants 
were detected using Atlas-SNP (version was 0.9.9.2) (http://code.google.com/p/atlas-snp/) 
with default parameters. Variant probability scores, which measure the probability of a 
substitution error at the SNP site were generated using the atlas_snp_evaluate.rb script with 
an estimated substitution error rate of 0.0008 and an estimated SNP rate of 0.001. Variant 
sites were called at positions containing 5 or more reads, sites with fewer than 5 reads were 
marked as no calls. Heterozygote positions were called when the alternate allele was present 
in 20-80% of the reads and contained an atlas probability score of greater than 1×10−5. 
Probable heterozygotes with a probability score of less than 1×10−5 were deemed unreliable 
and marked as a no call site. Variants were then compared to the HapMap Phase II and III 
genotypes and variant detection rate and concordance rate were calculated in the same 
manner described above for the Illumina GAII sequence data.
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Figure 1. Microdroplet PCR workflow
Primer Library Generation (A): (1) Identify targeted sequences of interest in the genome. 
(2) Design and synthesize forward and reverse primer pairs for each targeted sequence 
(library element). (3) Generation of primer pair droplets for each library element. A 
microfluidic chip is used to encapsulate the aqueous PCR primers in inert fluorinated carrier 
oil with a block-copolymer surfactant to generate the equivalent of a picoliter scale test tube 
compatible with standard molecular biology. (4) Primer library, primer pair droplets of 
library elements are mixed together so that each library element has an equal representation. 
Genomic DNA Template Mix Preparation (B): (5) Genomic DNA is biotinylated (red dots), 
fragmented into 2 to 4 kb fragments and purified. (6) Purified genomic DNA is mixed 
together with all of the components of the PCR reaction (DNA polymerase, dNTPs, and 
buffer) except for the PCR primers. Droplet Merge and PCR (C): (7) Primer Library 
droplets are dispensed to the microfluidic chip (8) while the Genomic DNA Template is 
delivered as an aqueous solution and template droplets are formed within the microfluidic 
chip. The primer pair droplets and template droplets are then paired together in a 1:1 ratio. 
(9) Paired droplets flow through the channel of the microfluidic chip to pass through a 
merge area where an electric field induces the two discrete droplets to coalesce into a single 
PCR droplet. The roughly 1.5 million PCR droplets are collected into a single 0.2 ml PCR 
tube. The collection of PCR droplets (PCR Library) is processed in a standard thermal cycler 
for targeted amplification, followed by breaking the emulsion of PCR droplets to release the 
PCR amplicons into solution for genomic DNA (gDNA) removal, purification and 
sequencing.
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Figure 2. Coverage plots of targeted sequences
For the validation phase (A) base by base coverage of three target sequences selected for 
their varying lengths and GC% amplified by microdroplet (blue) and traditional (red) PCR. 
For the scale-up phase (B) the coverage of two targets representing an average and 
maximum amplicon length sequenced by Illumina GA (green) and Roche 454 (yellow) is 
shown. At the bottom of each plot the PCR primer positions (grey dumbbells connected by 
line) are shown. Roche 454 end sequencing of average sized amplicons results in 2-fold 
higher coverage of middle bases whereas end sequencing of larger amplicons results in 
middle bases having no coverage.
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Figure 3. Normalized Coverage Distribution Plots
The validation phase 457 amplicons amplified by traditional PCR (A) and microdroplet PCR 
(B) and the scale-up phase 3976 amplicons amplified by microdroplet PCR (C). Normalized 
coverage is the absolute base coverage divided by the mean coverage of bases for the 
indicated sample. Each colored line represents either one of the six samples (A & B) or one 
of two sequencing platforms (C). The solid colored lines represent the cumulative 
distribution (left axis) for each sample. The colored dashed lines indicate a skewed normal 
distribution (right axis) for each sample. For each sample the mean coverage across all bases 
are listed.
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Figure 4. Inter-sample reproducibility of amplicon coverage
For the validation phase the normalized mean coverage of each amplicon is plotted for 
NA12006 (Caucasian) versus NA18505 (African) samples for the traditional (A) and 
microdroplet (B) PCR methods. For each sample (assigned same color as in Figure 2) the 
average normalized coverage of each amplicon is plotted for traditional versus microdroplet 
(C). Correlation matrix for all samples depicting Lin's concordance coefficient (D). All 
samples show a high correlation among each other within a PCR method but not between 
the two methods.
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